The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity.

IF 4.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart Failure Reviews Pub Date : 2025-02-17 DOI:10.1007/s10741-025-10495-1

Albulena Mecinaj, Victoria Vinje-Jakobsen, Doan T M Ngo, Aaron L Sverdlov, Peder L Myhre

引用次数: 0

Abstract

This mini-review highlights the results of the SARAH trial, which evaluated the efficacy of sacubitril/valsartan in preventing subclinical cardiac dysfunction in patients undergoing anthracycline-based chemotherapy. The trial demonstrated a significant reduction in GLS decline in the treatment group compared to placebo. The findings are discussed in context with other trials investigating neurohormonal blockade for the prevention of cancer therapy-related cardiac dysfunction.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart Failure Reviews 医学-心血管系统

CiteScore

10.40

自引率

2.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Heart Failure Reviews is an international journal which develops links between basic scientists and clinical investigators, creating a unique, interdisciplinary dialogue focused on heart failure, its pathogenesis and treatment. The journal accordingly publishes papers in both basic and clinical research fields. Topics covered include clinical and surgical approaches to therapy, basic pharmacology, biochemistry, molecular biology, pathology, and electrophysiology. The reviews are comprehensive, expanding the reader''s knowledge base and awareness of current research and new findings in this rapidly growing field of cardiovascular medicine. All reviews are thoroughly peer-reviewed before publication.